Month: March 2025

  • For the 2025 Global Media Summit, India will be geared

    For the 2025 Global Media Summit, India will be geared

    In a pivotal move to enhance international collaboration in the Media and Entertainment sector, the Government of India is set to engage with global stakeholders ahead of the World Audio Visual & Entertainment Summit (WAVES) 2025. Scheduled for March 13, 2025, at Sushma Swaraj Bhawan in New Delhi, this outreach event aims to gather participation for a crucial Global Media Dialogue, leading up to the inaugural WAVES Declaration in Mumbai on May 2, 2025.

    High-Level Participation and Objectives
    The outreach event will feature prominent figures, including Union Minister of External Affairs Dr. S. Jaishankar and Union Minister of Information and Broadcasting, Railways, and MeitY Shri Ashwini Vaishnaw. They will be joined by Union Minister of State for Information and Broadcasting & Parliamentary Affairs Dr. L. Murugan and Maharashtra Chief Minister Shri Devendra Fadnavis. Together, they will emphasize the transformative potential of WAVES as a unified global platform for the rapidly evolving Media and Entertainment sector. The event is expected to attract over 100 ambassadors and high commissioners, highlighting opportunities for collaborative efforts within the industry.

    Global Media Dialogue: Shaping the Future
    The Global Media Dialogue, part of WAVES 2025, aims to unite leaders, policymakers, industry stakeholders, media professionals, and artists to engage in meaningful discussions about the future of the audio-visual and entertainment sectors. Scheduled for May 2, 2025, in Mumbai, the dialogue will focus on fostering international collaboration, technological innovation, and ethical practices. A primary goal is to promote open communication and cooperation among nations to ensure fair and transparent growth in the Media and Entertainment sector.

    Key discussion points will include strategies for enhancing cross-border collaboration and creating a platform for knowledge-sharing. The dialogue will also address the importance of equitable access and growth for all stakeholders in the industry, ensuring that trade practices remain open and fair. By addressing common challenges and opportunities, the Global Media Dialogue aims to foster global harmony within the Media and Entertainment sector.

    WAVES 2025: A Premier Global Event
    WAVES 2025 is set to be a landmark event in the Media and Entertainment industry, taking place from May 1 to May 4, 2025, in Mumbai, Maharashtra. This premier global summit aims to connect India’s Media and Entertainment industry with the international market while simultaneously linking the global industry with India. The event seeks to foster growth, collaboration, and innovation, positioning India as a hub for content creation, intellectual property, and technological advancement.

    WAVES 2025 will feature various dynamic platforms designed to promote collaboration and innovation. The WAVES Bazaar will serve as a marketplace for business partnerships and content acquisition, introducing the first-ever e-bazaar for year-round global content trade. Additionally, the WaveXcelerator will connect startups in the Media and Entertainment sector with investors and mentors through live pitching sessions. The CreatoSphere will provide immersive experiences, including masterclasses, workshops, and a gaming arena, culminating in the WAVES CIC Awards. These initiatives aim to establish WAVES 2025 as a transformative event that drives a unified approach to the global Media and Entertainment industry.

    As the countdown to WAVES 2025 begins, the Government of India is poised to lead the way in fostering international collaboration and innovation within the Media and Entertainment sector. Observervoice

  • UK commits £23 million to foster telecom innovation

    UK commits £23 million to foster telecom innovation

    The UK government is driving innovation with a £23 million investment in telecommunications research. This fund focuses on areas such as 5G, quantum computing, and drone technologies. Technology Secretary Peter Kyle emphasizes its role in strengthening the UK’s leadership in connectivity, stating it would “cement the UK’s leadership in advanced connectivity and support projects delivering real, tangible change for people and businesses across Britain.”

    This funding will benefit seven key projects in UK regions, including Belfast, West Midlands, and Glasgow. Such initiatives aim for regional technological development and economic growth. Notably, £7 million will integrate 5G into businesses and public services, boosting infrastructure and service delivery. The remaining £15 million will go towards AI and cloud computing research, expanding these technologies for wider applications.

    Specifically, the Northeast Combined Authority will receive £1.9 million. This support covers the expansion of smart port solutions and enhances transport efficiency in the region. Moreover, local agriculture will benefit from wireless sensors used for soil and methane monitoring. Such an approach aims to improve automation, sustainability, and technological integration. These efforts seek to position the Northeast as a national hub for 5G innovation.

    Additional support includes £1.3 million to Belfast for the adoption of advanced wireless technologies, and £1 million to West Midlands to enhance Industry 4.0 technologies. These investments endorse the vision of evolving into a technologically advanced UK by 2035. VoiP

  • By 2028, the global IoT sector will be raised past $1.8T

    By 2028, the global IoT sector will be raised past $1.8T

    The global Internet of Things (IoT) market is poised to grow at a compound annual growth rate (CAGR) of 13.5% from $959.6 billion in 2023 to $1.8 trillion in revenue in 2028. This growth is driven by the rise of enterprise applications, enhanced by new technologies like 5G and AI. While IoT presents significant opportunities, challenges such as security concerns and fragmented standards must be addressed to ensure its widespread adoption and success, says GlobalData, a leading data and analytics company.

    GlobalData’s latest Strategic Intelligence report, “Internet of Things,” reveals that enterprise IoT will account for 72% of market revenue by 2028, up from 70% in 2023, while the consumer segment will make up 28% in 2028, down from 30% in 2023.

    New terrestrial wireless and satellite technologies will expand IoT connectivity options. Enhanced 5G now supports IoT use cases that demand lower complexity, reduced cost, and decreased power consumption. 5G-satellite non-terrestrial networks (NTN) is a new access technology that will enable devices in very remote locations to upload and download data via satellites. These new access technologies are ideal for devices that require continuous connectivity and extended battery life but do not need the full range of 5G features, such as higher bandwidth and lower latency.

    Artificial intelligence (AI) is increasingly important as an IoT catalyst. Artificial Intelligence of Things (AIoT) involves embedding AI into IoT devices, software, and services. Combining data collected by connected sensors and actuators with AI supports automated operations and predictive maintenance. AI can run in the cloud, on IoT devices directly with some limitations, or on both the cloud and the device.

    William Rojas, Research Director, Strategic Intelligence at GlobalData, comments: ”AIoT technologies in the form of embedded AI acceleration microprocessors, combined with the addition of new wireless access technologies, will act as a further catalyst for IoT adoption across enterprise and consumer sectors. Deployments that might have initially used only one type of IoT sensor are expanding to include a wide range of sensors as the cloud analytics processing capability continues to expand.”

    Security remains a concern for IoT deployments. The fragmented security standards landscape and weak security of many IoT devices could hold back further IoT adoption. Despite the ongoing industry efforts, there are no globally accepted IoT security standards. Many IoT devices have limited computing capacity and cannot run effective security software, leaving them and the networks to which they are connected vulnerable to cyberattacks.

    Rojas concludes: “Unlike other technological methods and tools such as AI, cybersecurity, and cloud computing, IoT is a digital ecosystem consisting of interdependent connectivity and data layers that aggregate, store, and process telemetric, image, and video data from IoT sensors. Embedded AIoT can also play a role in enhancing security at the IoT device level. Where more heavy compute resources are needed with low latency, then edge computing will be the best option.” GlobalData

  • Cloud-based network security solutions rise 18% as hardware falls 2%

    Cloud-based network security solutions rise 18% as hardware falls 2%

    According to a recently published report from Dell’Oro Group, the trusted source for market information about the telecommunications, security, networks, and data center industries, the Network Security market rebounded significantly in 4Q 2024, growing 9 percent year-over-year (Y/Y). For 2024, the market eclipsed $24 B, with SaaS and virtual-based solutions achieving robust 18 percent growth, offsetting a 2 percent decline in hardware revenue. Hardware revenue is expected to recover with a 5 percent rise in 2025, as enterprises balance cloud-first strategies with traditional hardware investments.

    “The remarkable rise of SaaS and virtual network security solutions has fundamentally reshaped enterprise cybersecurity strategies, creating a dynamic where hardware now trails cloud-based innovation,” said Mauricio Sanchez, Sr. Director, Enterprise Security and Networking at Dell’Oro Group. “Yet, physical appliances will regain modest momentum, particularly in segments like application delivery and high-performance firewalls, as inventory levels normalize and deferred upgrades resume.”

    Additional highlights from the 4Q 2024 Network Security Quarterly Report:

    • Firewall market revenue grew three percent Y/Y for the full year, propelled by the strong 22 percent growth in virtual firewall solutions amid the increasing adoption of hybrid and cloud environments.
    • The Security Service Edge (SSE) market grew 16 percent year over year for the full year. However, its growth has been decelerating, reflecting 2023 macroeconomic pressures and increasing market maturity.
    • Application Delivery Controllers (ADCs) grew eight percent Y/Y for the full year, bolstered by deferred physical hardware refreshes, despite an ongoing shift toward virtual and cloud-native ADC deployments.
    • Web Application Firewall (WAF) annual revenue increased 19 percent Y/Y, driven by cloud-native deployments and the evolving threat landscape.
    • The Network Security market is forecast to grow 11 percent in 2025, boosted by continued strength in cloud solutions and recovery in hardware spending.

    Dell’Oro

  • USD 101.86B will be the market for clinical trial services

    USD 101.86B will be the market for clinical trial services

    The global clinical trial services market, valued at USD 60.76 billion in 2024, is forecasted to grow at a robust CAGR of 8.9%, reaching USD 66.59 billion in 2025 and an impressive USD 101.86 billion by 2030. Factors such as the growing focus on patient-centric clinical trials such as Decentralized Clinical trials (DCTs) and the increasing number of clinical trials for precision/personalized medicines are supporting the growth of this market. Moreover, the upcoming therapeutic drugs patent cliff is propelling major pharmaceutical companies to heavily invest in R&D and outsource their clinical trial service. Additionally, CROs offer service flexibility which enables sponsors to modify their outsourcing strategies and optimize costs by paying only for required resources and expertise. Additionally, the rise in pediatric clinical trials for various therapeutic drugs and increasing pressure from regulatory bodies to conduct diversified clinical trials offer growth opportunities for CROs offering these specialized services. However, challenges associated with the cybersecurity of patient data and sponsors’ intellectual properties, and patient retention during trials hinder the growth of the market to a certain extent.

    By based on modality, the clinical trial services market is divided into small molecules, biologics, and medical devices. The large share of the small molecules clinical trial segment can be attributed to the established role of these drug modalities in drug development across various therapeutic areas. Small molecules have a high oral bioavailability, making them more convenient for patients compared to biologics. Additionally, pharmaceutical companies continue to invest in small molecule research due to their cost-effectiveness, stability, and ability to target intracellular pathways, maintaining their dominance in clinical trials.

    By on therapy area, the clinical trial services market is segmented into oncology, neurology, infectious diseases, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. The oncology segment accounted for the largest share of the clinical trial services market by therapy area in 2024. The large share of this segment is attributed to the increase in global cancer cases due to aging populations and lifestyle factors, supported by rising demand for new treatments. For this reason, pharmaceutical companies are increasingly investing and collaborating with CROs to develop advanced oncology drugs. This dominance is expected to continue throughout the forecast period as major players are developing new technologies for better oncology treatment.

    By geography, the clinical trial services market is divided into six regions, North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2024, North America held the largest share of the clinical trial services market, followed by Europe. Aisa Pacific registered the highest CAGR growth within the clinical trial services market during the forecast period owing to its large patient population, high prevalence of chronic and infectious diseases, and increasing focus on developing biologics, biosimilars, and advanced therapies. Global pharmaceutical companies are increasingly relocating manufacturing and clinical research to the region to leverage cost benefits, regulatory advancements, and improved patient retention in trials. Additionally, government support and rising investments in clinical research have further accelerated the outsourcing of clinical trial activities to APAC. MarketsandMarkets

  • How to address medical equipment’ security flaws

    How to address medical equipment’ security flaws

    The adoption of connected medical devices, collectively called the Internet of Medical Things (IoMT), has transformed patient care. However, this technological advancement has also introduced cybersecurity challenges to safeguard patient safety and uphold organizational security.

    Securing IoMT: Prioritizing risks
    IoMT devices, ranging from infusion pumps to imaging systems, are often interconnected and communicate over networks, making them potential entry points for cyber threats. The unique nature of medical devices, often running on legacy systems with extended lifecycles, compounds the complexity of securing them.

    “Healthcare organizations are constantly battling to manage devices with high CVSS scores of 9.0 and above. We found 20% of OT and IoMT devices fall into this high-risk category. Of course, these CVSS scores are valuable. However, they are often relied on when prioritizing which ones to fix. Organizations are trying to “boil the ocean” when dealing with vulnerabilities,” Ty Greenhalgh, Industry Principal for Healthcare at Claroty, told Help Net Security.

    “To truly manage and prioritize risks, organizations need to look beyond technical scores and consider contextual risk factors that impact operations related to patient care. This can include identifying devices in critical care areas, legacy devices close to or past their end-of-life status, where any insecure communication protocols are, and how sensitive personal information is being stored,” Greenhalgh added.

    Security weaknesses in medical devices
    1. Legacy systems and outdated firmware
    A significant number of medical devices operate on outdated operating systems. Studies have shown that 14% of connected medical devices run on unsupported or end-of-life operating systems, with imaging devices like x-ray and MRI systems comprising 32% of these unsupported devices. This reliance on obsolete software renders them susceptible to known exploits.

    2. Default and weak authentication
    Alarmingly, 21% of medical devices are secured by weak or default credentials, which are often easily obtainable from online manuals. This oversight provides a gateway for attackers to infiltrate hospital networks.

    3. Unsegmented networks
    Approximately 22% of hospitals have devices that bridge guest and internal networks. Shockingly, 4% of surgical devices communicate over guest networks, exposing critical equipment to potential attacks from public access points.

    4. Lack of visibility and inventory management
    Many healthcare organizations lack a comprehensive inventory of their connected devices. This absence of visibility hampers effective monitoring and risk assessment, leaving numerous devices unmonitored and vulnerable.

    The cost of inaction
    1. Attacks
    The healthcare sector has become a prime target for ransomware attacks. In 2024, 92% of healthcare organizations experienced at least one cyberattack, with 69% reporting disruptions to patient care as a direct consequence.

    2. FDA warnings and device recalls
    In March 2019, the FDA issued warnings concerning cybersecurity vulnerabilities in Medtronic’s implantable cardiac devices. The identified flaws could have allowed unauthorized users to access and control these devices, posing severe risks to patient safety.

    3. Nation-state threats
    APTs have increasingly targeted healthcare infrastructures. These sophisticated attacks often aim to exfiltrate sensitive patient data or disrupt critical services, underscoring the necessity for robust defense mechanisms.

    Regulatory and compliance challenges
    1. FDA and medical device security regulations
    The FDA has emphasized the importance of cybersecurity in medical devices, issuing guidelines that urge manufacturers to incorporate security measures throughout the device lifecycle. Compliance with these guidelines is essential to ensure both patient safety and regulatory approval.

    2. HIPAA and IoMT
    The Health Insurance Portability and Accountability Act (HIPAA) mandates the protection of patient information. Medical devices that handle protected health information (PHI) must adhere to HIPAA’s stringent security requirements to prevent unauthorized access and data breaches.

    3. EU MDR and GDPR implications
    The European Union’s Medical Device Regulation (MDR) and General Data Protection Regulation (GDPR) impose strict standards on medical device security and data protection. Non-compliance can result in substantial fines and legal repercussions, making it imperative for organizations to align their practices with these regulations.

    Proactive engagement
    “For CISOs, the priority should be proactive engagement. First, implement real-time vulnerability tracking and ensure security patches can be deployed quickly without disrupting device functionality. Medical device security must be continuous—not just a checkpoint during development or regulatory submission. Second, regulatory alignment isn’t a one-time effort. The FDA now expects ongoing vulnerability monitoring, coordinated disclosure policies, and robust software patching strategies. Automating security processes—whether for SBOM (Software Bill of Materials) management, dependency tracking, or compliance reporting—reduces human error and improves response times. An SBOM is valuable not just for compliance but as a tool for tracking and mitigating vulnerabilities throughout a device’s lifecycle,” Ken Zalevsky, CEO of Vigilant Ops explained.

    “Finally, collaboration is essential. Medical device cybersecurity is a shared responsibility across manufacturers, healthcare providers, and regulators. Establishing clear, repeatable processes for assessing supplier risk and securing software supply chains will reduce exposure to threats like ransomware and zero-day exploits,” Zalevsky added.

    Risk mitigation strategies
    Building a medical device security framework:

    • Asset inventory and risk assessment: Conduct thorough inventories of all connected medical devices and perform regular risk assessments to identify and prioritize vulnerabilities.
    • Network segmentation and microsegmentation: Implement network segmentation to isolate medical devices from other critical systems, reducing the potential impact of a compromised device.
    • Zero trust architecture: Adopt a zero trust model, enforcing strict access controls and continuous verification for all devices and users within the network.

    Improving vendor security management:

    • Accountability for security updates: Establish clear agreements with device manufacturers, holding them responsible for timely security patches and updates.
    • Software Bill of Materials (SBOM): Require vendors to provide an SBOM, offering transparency into the components and software within each device to better assess potential vulnerabilities.

    Leveraging AI and threat intelligence:

    • Anomaly detection: Utilize artificial intelligence to monitor device behavior and detect anomalies that may indicate a security breach.
    • Threat intelligence sharing: Participate in information-sharing initiatives to stay informed about emerging threats and vulnerabilities.

    Incident response and resilience planning:

    • IoMT-specific response plans: Develop incident response plans tailored to medical device security incidents, ensuring rapid containment and mitigation.
    • Regular drills and simulations: Conduct tabletop exercises and simulations to prepare for potential cyber incidents, enhancing organizational readiness and response capabilities.

    “The rate at which digital transformation is onboarding new devices onto the network is outpacing organizations’ abilities to track where these assets are or how they’re performing. This can lead to underutilised assets that needlessly drain budgets. CISOs must improve their understanding of how assets interact with the network to identify areas of wasteful spending and pinpoint opportunities to optimise underutilised technology. To do this, they need to embrace a visibility first mindset and establish a robust asset management system. This is essential to maximise resources and minimise financial losses,” Greenhalgh explained

    “To aid this, security leaders must break down knowledge silos within their organizations. CISOs should review their current policies and engage knowledgeable stakeholders from across the organization. Clinical engineers, for instance, hold invaluable insights into the technologies behind medical devices, yet they are often excluded from asset management and network security discussions,” Greenhalgh concluded. Help Net Security

  • Revenue from the robotic radiotherapy market projected to reach USD 2.95B

    Revenue from the robotic radiotherapy market projected to reach USD 2.95B

    The global robotic radiotherapy market size is projected to grow at a CAGR of 11.6% from 2026 to 2032, according to Verified Market Research®. The report reveals that the market was valued at USD 1.23 billion in 2024 and is expected to reach USD 2.95 billion by the end of the forecast period.

    The robotic radiotherapy market is experiencing rapid growth due to increasing demand for non-invasive cancer treatments. Robotics and AI-driven technologies are transforming the field of oncology, enabling targeted tumor eradication while minimizing damage to surrounding healthy tissues. As healthcare facilities embrace automation, the market is set to expand, offering improved treatment efficiency and accuracy.

    Key market drivers
    Rising cancer incidence driving demand for precision treatment: The rising global incidence of cancer is driving the desire for sophisticated treatment options, with robotic radiation becoming a favored approach. Conventional radiation therapy frequently suffers from imprecision, resulting in unintended harm to healthy tissues. Robotic radiotherapy, combined with artificial intelligence and motion-tracking technology, increases precision, decreases treatment duration, and boosts patient results. With the increasing incidence of cancer, healthcare providers and oncology centers are diligently investing in these technologies to enhance care delivery.

    Advancements in AI and machine learning in radiation therapy: The amalgamation of artificial intelligence (AI) and machine learning (ML) is transforming robotic radiotherapy through real-time tumor tracking, automated treatment planning, and adaptive radiation dosage administration. These technologies augment accuracy, reduce errors, and promote efficiency in cancer therapy. Prominent medical device manufacturers are significantly spending in research and development to integrate AI-driven analytics, hence accelerating market acceptance. As healthcare organizations pursue automation and efficiency, AI-driven robotic radiotherapy is emerging as an industry standard.

    Growing preference for non-invasive cancer treatment modalities: The transition to non-invasive cancer therapies is hastening the implementation of robotic radiation systems. In contrast to traditional surgery, robotic radiation provides a non-invasive option that decreases recovery duration, mitigates surgical complications, and enhances patient comfort. The demand for outpatient cancer therapies is increasing, hence intensifying the necessity for robotic solutions. As healthcare institutions emphasize patient-centered care and operational efficiency, global investments in robotic radiotherapy technology are anticipated to increase significantly.

    Market restraints hindering the market growth
    High capital investment and operational costs: Notwithstanding its technological benefits, robotic radiotherapy necessitates considerable financial commitment, constraining its adoption by small and medium-sized healthcare institutions. The expenses associated with acquiring, installing, and sustaining robotic systems are considerably greater than those for traditional radiation therapy apparatus. Moreover, continuous maintenance, software enhancements, and specialized training for healthcare personnel contribute to operational costs. These budgetary limitations present a significant obstacle to extensive market penetration.

    Stringent regulatory approvals slowing market growth: The regulatory intricacies associated with robotic radiotherapy systems pose a considerable obstacle for manufacturers and healthcare organizations. Rigorous approval procedures enforced by regulatory agencies including the FDA, EMA, and various regional health authorities impede product commercialization. Adherence to safety and efficacy criteria necessitates comprehensive clinical trials, hence prolonging the time-to-market for novel developments. This legislative impediment hinders the swift implementation of robotic radiotherapy technology, affecting total market growth.

    Limited availability of skilled healthcare professionals: The effective execution of robotic radiotherapy depends on proficient specialists, such as oncologists, radiation therapists, and medical physicists, who are trained in robotic-assisted treatment planning and implementation. Nonetheless, a deficiency of skilled professionals continues to pose a significant barrier, especially in developing countries. The deficiency in proficiency regarding modern robotic systems may result in operational inefficiencies and impede adoption. Addressing this skill gap through targeted training programs and certifications is crucial for market expansion.

    Geographical dominance:
    North America dominates the robotic radiotherapy market with advanced healthcare infrastructure

    North America dominates the Robotic Radiotherapy Market, propelled by robust healthcare infrastructure, significant adoption of AI-enhanced radiation therapy, and considerable investments in cancer treatment technology. The United States excels owing to advantageous payment rules, substantial research and development in robotic oncology, and an increasing incidence of cancer. Simultaneously, the Asia-Pacific region is seeing swift expansion, driven by rising healthcare expenditures and enhanced access to sophisticated radiation technologies. Verified Market Research

  • Stephen Curry will likely be the first player to score 4,000 3-pointers in his career

    Stephen Curry will likely be the first player to score 4,000 3-pointers in his career

    The NBA’s all-time leader in 3-pointers made enters Thursday just two triples shy of the milestone.

    When the Warriors host the Kings on Thursday (10 ET, TNT/TruTV/Max), Stephen Curry’s latest shooting milestone will be within reach — needing only two 3-pointers to become the first player in NBA history to reach 4,000 career 3-pointers made.

    Curry became the all-time leader in 3-pointers made on Dec. 14, 2021, when he splashed his 2,974th career triple to break the mark previously held by Ray Allen.

    It’s been 1,180 days since that night at Madison Square Garden. Curry played in 221 games and made another 1,012 3-pointers since then, putting him on the precipice of starting his own shooting club.

    Curry was the first player to reach 3,000 career 3-pointers made and has since been joined by James Harden (3,117). While Damian Lillard (2,785) and former teammate Klay Thompson (2,657) are approaching 3,000 as well, Curry is alone as he nears 4,000.

    The road to this milestone moment began in 2009 when the Warriors selected Curry with the seventh overall pick in the Draft. As a rookie, Curry finished 10th in 3-pointers made with 166. It would be his lowest ranking in all but two seasons in his 16-year career — and both of those were cut short due to injuries.

    Curry has led the NBA in total 3-pointers made in eight of his 16 seasons, including his record 402 3-pointers in 2015-16, when he became the first unanimous Kia MVP. Curry has more seasons with 300+ 3-pointers made (five) than all other players in the NBA combined (James Harden and Thompson have the only other two).

    Harden and Thompson also rank second to Curry in games with at least five and 10 3-pointers made, respectively.

    Curry’s 388 games with five-plus 3-pointers made is one more than second and third place combined (387 by Harden and Damian Lillard). Meanwhile, Curry’s 26 games with 10-plus 3-pointers made is more than the next five players combined.

    Curry has 14 games in his career with 11 or more 3-pointers, including one this season (Feb. 27) when he splashed a dozen 3-pointers in a road win vs. the Magic.

    During that game against Orlando, Curry hit his longest shot of the season — a 51-footer from beyond half court to beat the halftime buzzer. The shot gave Curry 21 points at the half, which he followed with a 35-point second half to finish with 56 points — the fourth-highest scoring game of his career.

    As the shot chart above illustrates, Curry is not afraid of taking shots from beyond half court and risking damage to his shooting percentage. Over his career, Curry has hit six backcourt shots in 113 attempts (5.3%), while still ranking fourth in career 3-point percentage (42.4%) among 161 players with at least 1,000 3-pointers made.

    “He was due for one of those,” Warriors coach Steve Kerr said. “One of the many things I love about Steph, he always shoots the half-court shots, he doesn’t care about his percentage. He’s had so many the last couple years that were right there and as soon as he let it go I said that’s in. I just felt it.”

    Consistency is a key factor in Curry’s road to 4,000 career made 3-pointers. While all shooters go through slumps, Curry has never played three consecutive games without making at least one 3-pointer.

    Curry has made at least one 3-pointer in 967 of his 1,010 career games. That 95.7% rate ranks first all-time among players that have played at least 50 games. Only 186 players in NBA history have ever played in 967 games, let alone have that many games with a 3-pointer.

    Curry not only holds the record for most consecutive games with at least one 3-pointer made (268 games over five seasons from 2018-2023), he also owns the second-longest streak (157 games, 2014-2016).

    All of this adds up to a shooting resume unlike any the game has ever seen. And with two more 3s, Curry will add another accolade to the list. NBA

  • A review of NBA player Junior Bridgeman’s business ventures and the way he built a $1.4B empire

    A review of NBA player Junior Bridgeman’s business ventures and the way he built a $1.4B empire

    Billionaire entrepreneur and ex-NBA player Junior Bridgeman died after suffering a medical emergency at a public event on Tuesday. He was 71.

    Bridgeman played in the NBA for 12 years, from 1975 to 1987, during which he was a key player for the Milwaukee Bucks and the Los Angeles Clippers.

    In response to his passing, the Milwaukee Bucks issued a statement, saying, “We are shocked and saddened by the tragic passing of Bucks legend and owner Junior Bridgeman.”

    “Junior’s retired No. 2 jersey hangs in Fiserv Forum, serving as a constant remembrance of his outstanding play on the court and his impact on the Bucks’ success. His hard work and perseverance led him to become one of the nation’s top business leaders and, last September, Junior’s professional life came full circle when he returned to the Bucks family as an owner. His memory will always be an inspiration to the Bucks organization.”

    Junior Bridgeman’s entrepreneurial journey –
    Bridgeman began investing in Wendy’s franchises during his NBA career. Upon retiring from professional basketball, he became the owner and CEO of Bridgeman Foods, overseeing the operation of over 450 Wendy’s and Chili’s restaurants across 20 states until 2016, WDRB reported.

    He also served as an independent bottler for Coca-Cola. Additionally, Bridgeman’s family acquired Ebony and Jet magazines. He was also a co-owner of the Valhalla Golf Club in Louisville.

    In September 2024, Bridgeman made a significant move by purchasing a 10% stake in the Milwaukee Bucks, a deal that valued the franchise at $4 billion.

    Bridgeman served as Chairman of the University of Louisville’s Board of Trustees from 2003 to 2005 and briefly returned to the board in 2016. He also held positions on several boards, including Fifth Third Bank, the Louisville Free Public Library, West End School, and the Crusade for Children Foundation. Additionally, he co-chaired the capital campaign for the African American Heritage Foundation.

    Bridgeman was also a part of the original board of the Louisville Arena Authority, which played an important role in securing financing for KFC Yum! Center.

    Junior Bridgeman’s net worth –
    While Bridgeman earned around $350,000 a year during his NBA career, his business ventures propelled his wealth to an estimated net worth of $1.4 billion, according to Forbes. His financial success made him one of the wealthiest former athletes in the world. Hindustan Times

  • Rohit Sharma talks his odds of starring in the 2027 ICC Men’s Cricket World Cup

    Rohit Sharma talks his odds of starring in the 2027 ICC Men’s Cricket World Cup

    India captain Rohit Sharma says he is keeping all his options open when it comes to his future playing career – although he added that he cannot commit to being part of the next ICC Men’s Cricket World Cup in 2027.

    “It’s very hard to say that right now,” he said on the prospect of taking part in the showcase in two years’ time, “but I’m keeping all my options open. I want to see how well I’m playing.

    “Right now, I’m playing really, really well, and I’m enjoying everything I’m doing with this team, and the team is enjoying my company as well, which is nice.

    “I can’t really say 2027, because it’s too far, but I’m keeping all my options open.”

    Having led India to victory in the ICC Men’s Champions Trophy 2025 – and been named Player of the Match in the final – Rohit had told a press conference that rumours that he was planning to retire were unfounded.

    He also elaborated on what it is about the current India squad that keeps him wanting to be part of it, despite his 38th birthday approaching next month.

    “As long as I’m enjoying the sport, I’m enjoying playing the game, doing what I’m doing for this team, I will continue to play,” he said.

    “It is something that really makes me happy. There are a lot of things involved, there’s so much pride, and the way this team is playing, I don’t want to leave this team.

    “The way we are playing at this point in time, there is so much joy, so much fun to play with all of them.” ICC-Cricket